Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate cancer (specifically the type called adenocarcinoma), confirmed through a tissue or cell sample.
- People who are generally able to carry out daily activities with no or minimal limitations (based on a standard medical scale called ECOG, scored 0 or 1).
- People whose PSA (a protein measured in the blood that can indicate prostate cancer activity) is at least 2 ng/mL at the time of screening.
- People whose prostate cancer has continued to grow or spread despite hormone-lowering therapy (ADT) and at least one other approved hormonal treatment for castration-resistant prostate cancer.
Who may not be able to join:
- People who have a history of cancer that has spread to the brain.
- People who have reduced heart function or a significant heart condition.
- People who have a serious medical condition — such as an active or uncontrolled infection, a mental health condition, or abnormal laboratory results — that the supervising doctor believes would make participation unsafe or not possible.
Important: Other eligibility criteria set out in the trial protocol may also apply, and the trial site is the appropriate contact for confirming whether a person meets all requirements. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs); Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria; Number of participants with AEs leading to study intervention discontinuation; Number of deaths
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.